By Professor Richard Bryan Lock

Journal articles

Whiteford CC; Bilke S; Greer B; Chen Q; Braunschweig TA; Cenacchi N; Wei JS; Smith MA; Houghton PJ; Morton CL; Reynolds CP; Lock RB; Gorlick R; Khanna C; Thiele CJ; Takikita M; Catchpoole DR; Hewitt SM; Khan J, 2007, 'Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis', Cancer research, 67, pp. 32 - 40

Bachmann PS; Gorman R; Papa R; Marshall GM; Lock RB, 2007, 'Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia', Cancer research, 67, pp. 4482 - 4490

Bachmann PS; Lock RB, 2007, 'In vivo models of childhood leukemia for preclinical drug testing', Current Drug Targets, 8, pp. 773 - 783

Xue C; Haber M; Flemming C; Marshall GM; Lock RB; Mackenzie K; Norris MD; Gurova K; Gudkov A, 2007, 'p53 determines multidrug sensitivity of childhood neuroblastoma.', Cancer research, 67, pp. 10351 - 10360

Morton CL; Papa RA; Lock RB; Houghton PJ, 2007, 'Preclinical chemotherapeutic tumor models of common childhood cancers: solid tumors, acute lymphoblastic leukemia and disseminated neuroblastoma', Curent Protocols in Pharmacology, pp. 14.8.1 - 18.4.20

Houghton P; Morton C; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb A; Zhang W; Lock RB; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA, 2007, 'The Paediatric Preclinical Testin Program: Description of models and early testing results.', Pediatric Blood and Cancer, 49, pp. 928 - 940

Lee E; Bachmann PS; Lock RB, 2007, 'Xenograft models for the preclinical evaluation of new therapies in acute leukemia', Leukemia and Lymphoma, 48, pp. 659 - 668

Shaw SE; Haylock DN; Johnston HM; Lock R; Nilsson SK, 2006, 'The Role of Hyaluronic Acid in Normal and Perturbed Hemopoietic Stem Cell Biology.', Blood, 108, pp. 708 - 708, http://dx.doi.org/10.1182/blood.v108.11.708.708

Houghton PJ; Maris JM; Friedman HS; Keir ST; Lock RB; Gorlick R; Kolb EA; Reynolds CP; Morton C; Smith MA, 2006, 'Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor ispinesib (SB-715992)', EJC SUPPLEMENTS, 4, pp. 98 - 98, http://dx.doi.org/10.1016/S1359-6349(06)70318-4

Smith MA; Maris JM; Keir ST; Friedman HS; Lock RB; Kolb EA; Keshelava N; Reynolds CP; Morton C; Houghton PJ, 2006, 'Pediatric preclinical testing program (PPTP) evaluation of the Src-Abl inhibitor dasatinib (BMS-354825)', EJC SUPPLEMENTS, 4, pp. 101 - 101, http://dx.doi.org/10.1016/S1359-6349(06)70327-5

Smith MA; Maris JM; Keir ST; Lock RB; Gorlick R; Kolb EA; Keshelava N; Reynolds CP; Morton C; Houghton PJ, 2006, 'Pediatric preclinical testing program (PPTP) evaluation of the VEGFR-2 inhibitor AZD2171', EJC SUPPLEMENTS, 4, pp. 34 - 35, http://dx.doi.org/10.1016/S1359-6349(06)70108-2

Xu B; Wang BJ; Li AM; Lock R, 2006, 'Effect of glucocorticoid on the expression of Puma in acute lymphoblastic leukemia', Chinese Journal of Contemporary Pediatrics, 8, pp. 151 - 154

Mackenzie K; Lock RB, 2006, 'An endothelial metronome breast cancer?', Blood, 108, pp. 407 - 408

Verrills NM; Liaw TY; Lock RB; Kavallaris M; Liem N; Hood B, 2006, 'Proteomic anlaysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study', Proteomics, 6, pp. 1681 - 1694

Hsu AK; Kerr BA; Jones KL; Lock RB; Hart DN; Rice AM, 2006, 'RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy', Biology of Blood and Marrow Transplantation, 12, pp. 855 - 867

Wen VW; Wu K; Baksh S; Hinselwood RA; Lock RB; Clark SJ; Moore MA; Mackenzie K, 2006, 'Telomere-driven karyotypic complexity concurs with p16INK4a inactivation in TP53 competent immortal endothelial cells', Cancer research, 66, pp. 10691 - 10700

Houghton PJ; Morton CL; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb EA; Zhang W; Lock RB; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA, 2006, 'The Pediatric Preclinical Testing Program: description of models and early testing results', Pediatric Blood and Cancer

Choo A; Palladinetti P; Passioura TJ; Shen S; Symonds GP; Dolnikov A, 2006, 'The role of IRF1 and IRF2 transcription factors in leukaemogenesis', Current Gene Therapy, 6, pp. 543 - 550

Choo A; Palladinetti P; Passioura T; Shen S; Lock R; Symonds G; Dolnikov A, 2006, 'The role of IRF1 and IRF2 transcription factors in leukaemogenesis', Current Gene Therapy, 6, pp. 543 - 550

Bachmann PS; Gorman R; MacKenzie KL; Lutze-Mann L; Lock RB, 2005, 'Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor', Blood, 105, pp. 2519 - 2526

Markovic A; Mackenzie K; Lock RB, 2005, 'FLT-3: a new focus in the understanding of acute leukemia', International Journal of Biochemistry and Cell Biology, 37, pp. 1168 - 1172

Liem N; Papa R; Milross CG; Schmid M; Tajbakhsh M; Choi S; Ramirez C; Rice AM; Haber M; Norris MD; Lock RB, 2004, 'Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies', Blood, 103, pp. 3905 - 3914, http://dx.doi.org/10.1182/blood-2003-08-2911

Taylor LM; James A; Schuller C; Brce J; Lock RB; Mackenzie K, 2004, 'Inactivation of p16INK4a, with retention of pRB and p53/p21cip1 function, in human M3C5 fibroblasts that overcome a telomere-independent crisis during immortalization', The Journal of Biological Chemistry, 279, pp. 43634 - 43635

Bendall LJ; Nilsson SK; Khan NI; Bonnet C; Lock RB; papa R; Bradstock KF; Gottlieb DJ, 2004, 'Role of CD44 variant exon 6 in acute lymphoblastic leukemia: Association with altered bone marrow localisation and inceased tumor burden.', Leukemia, 18, pp. 1308 - 1319

Lock RB, 2003, 'TCL1: A new drug target in lymphoid and ger-cell malignancies', International Journal of Biochemistry and Cell Biology, 35, pp. 1614 - 1618

Houghton PJ; Adamson PC; Blaney S; Fine HA; Gorlick R; Haber M; Helman L; Hirschfeld S; Hollingshead MG; Israel MA; Lock RB; Maris JM; Merlino G; Patterson W; Reynolds CP; Shannon K; Yu A; Yu J; Smith MA, 2002, 'Testing of new agents in childhood cancer preclinical models(meeting summary)', Clinical Cancer Research, 8, pp. 3646 - 3657

Lock RB; Liem N; Farnsworth ML; Milross CG; Xue C; Tajbakhsh M; Haber M; Norris MD; Marshall GM; Rice AM, 2002, 'The non-obese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of Childhood acute lymphblastic leukemia reveals intrinsic differences in biological characteristics at diagnosis and relapse', Blood, 99, pp. 4100 - 4108

Catts VS; Haber M; Norris MD; Lutze-Mann L; Lock RB, 2001, 'High Level resistance to Glucocorticoids, assosiated with a dysfunctional glucocorticoid receptor, in childhood acute lymphoblastic leukemia cells selected for methotrexate resistance', Leukemia, 15, pp. 929 - 935

Marshall GM; Norris MD; Lock RB; Peaston AE; Gardaneh M; Franco VA; Hocker JE; Murphy K; Farnsworth ML; Catchpoole DR; Haber M, 2001, 'MRP1 gene expression level regulates the death and differentation response of neuroblastoma cells', British Journal of Cancer, 85, pp. 1564 - 1571, http://dx.doi.org/10.1054/bjoc.2001.2144

Catchpoole DR; Lock RB, 2001, 'The Potential Tumour Suppressor role for caspase-9 in the childhood malignancy, neoroblastoma', European Journal of Cancer, pp. 2217 - 2221

Murphy KD; Streips UN; Lock RB, 2000, 'Bcl-2 inhibits a Fas-induced conformational change in the Bas N terminus and Bax mitchondrial translocation', The Journal of Biological Chemistry, pp. 17225 - 17228

Murphy KD; Ranganathan V; Farnsworth ML; Kavallaris M; Lock RB, 2000, 'Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumour cells', Cell death and differentiation, pp. 102 - 111

Turnbull RM; Meczes EL; Rogers MP; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA, 1999, 'Carbamate analogues of amsacrine active against non-cycling cells: Relative activity against topoisomerases IIα and β', Cancer Chemotherapy and Pharmacology, 44, pp. 275 - 282, http://dx.doi.org/10.1007/s002800050978

Murphy KD; Streips UN; Lock RB, 1999, 'Bax membrane insertion during Fas (CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2', Oncogene, 18, pp. 5991 - 5999

Elliott MJ; Murphy KD; Stribinskiene L; Ranganathan V; Sturges E; Farnsworth ML; Lock RB, 1999, 'Bcl-2 inhibits early apoptotic events and reveals post-mitotic multinucleation without affecting cell cycle arrest in human epithelial tumor cells exposed to etoposide', Cancer Chemotherapy and Pharmacology, pp. 1 - 11

Turnbull RM; Meczes EL; Rogers M; Lock RB; Sullivan DR; Finlay GJ; Baguley BC; Austin CA, 1999, 'Carbanate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases II and B', Cancer Chemotherapy and Pharmacology, pp. 275 - 282

Elliot M; Stribinskiene L; Lock RB, 1998, 'Expression of Bcl-2 in human epithelial tumor (HeLA) cells enhances clonogenic survival following exposure to 5-fluoro-2-deoxyuridine or staurosporine, but not following exposure to etoposide or dosorubicin', Cancer Chemotherapy and Pharmacology, pp. 457 - 463

LaRocca RV; Lock RB, 1998, 'Surveying the frontiers of cancer research and therapy', Louisville Medicine, 45, pp. 511 - 513

Lock RB; Thompson BS; Sullivan DM; Stribinskiene L, 1997, 'Potentiation of etoposide-induced apoptosis by staurosporine in human tumor cells is associated with events downstream of DNA-protein complex formation', Cancer Chemother Pharmacol, 39, pp. 399 - 409

Lock RB; Thompson BS; Stribinskiene L, 1996, 'Differential ability of 2,4-dinitrophenol to modulate etoposide cytotoxicity in mammalian tumor cell lines associated with inhibition of macromolecular synthesis', Int J Oncology, 8, pp. 305 - 311

Lock RB; Stribinskiene L, 1996, 'Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival', Cancer Research, 56, pp. 4006 - 4012

Sullivan DM; Feldhoff PW; Lock RB, 1995, 'Characterization of an altered DNA topoisomerase IIα from a mitoxantrone resistant mammalian cell line which is hypersensitive to DNA crosslinking agents', Int J Oncology, 7, pp. 1383 - 1393

Eastman A; Grant S; Lock R; Tritton T; Van Houten N; Yuan J, 1994, 'Cell Death in Cancer and Development', Cancer Research, 54, pp. 2812 - 2818

Lock RB; Galperina OV; Feldhoff RC; Rhodes LJ, 1994, 'Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells', Cancer Research, 54, pp. 4933 - 4939

Lock RB; Keeling PK, 1993, 'Responses of HeLa and Chinese hamster ovary p34cdc2/cyclin-B kinase in relation to cell cycle perturbations induced by etoposide', Int J Oncology, 3, pp. 33 - 42

Lock RB, 1992, 'Inhibition of p34cdc2 kinase activation, p34cdc2 tyrosine dephosphorylation, and mitotic progression in Chinese hamster ovary cells exposed to etoposide', Cancer Research, 52, pp. 1817 - 1822

Webb CD; Latham MD; Lock RB; Sullivan MD, 1991, 'Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line', Cancer Research, 51, pp. 6543 - 6549

Lock RB; Ross WE, 1990, 'Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells', Cancer Research, 50, pp. 3761 - 3766

Lock RB; Ross WE, 1990, 'Possible role for p34cdc2 kinase in etoposide-induced cell death of Chinese hamster ovary cells', Cancer Research, 50, pp. 3767 - 3771

Shen J-W; Subjeck JR; Lock RB; Ross WE, 1989, 'Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response', Mol Cell Biol, 9, pp. 3284 - 3291

Back to profile page